<prof_article_slide_presentation>
  <front_label>Front Matter</front_label>
  <above_title/>
  <title>
    <p>HIV Attachment and Entry: Pursuing a Challenging Target</p>
  </title>
  <contrbtr_pre_content>
    <p>WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.</p>
  </contrbtr_pre_content>
  <contrbtr_byline>
    <p>Peter Kwong, PhD</p>
  </contrbtr_byline>
  <contrbtr_group>
    <contrbtr_type_lbl>Faculty</contrbtr_type_lbl>
    <contrbtr_element chronicleid="0901c79180d66056">
      <contrbtr_nm>Peter D. Kwong, PhD</contrbtr_nm>
      <contrbtr_title>
        <p>Chief, Structural Biology Section and Structural Bioinformatics Core Section, Vaccine Research Center, NIAID/NIH, Bethesda, MD, United States</p>
      </contrbtr_title>
      <contrbtr_bio/>
      <contrbtr_disclsr>
        <p>Disclosure: Peter D. Kwong, PhD, has disclosed no relevant financial relationships.</p>
      </contrbtr_disclsr>
    </contrbtr_element>
  </contrbtr_group>
  <contrbtr_group>
    <contrbtr_type_lbl>Editors</contrbtr_type_lbl>
    <contrbtr_element>
      <contrbtr_nm>Marinella Calle, PhD, CMPP</contrbtr_nm>
      <contrbtr_title>
        <p>Scientific Director, WebMD Global, LLC</p>
      </contrbtr_title>
      <contrbtr_bio/>
      <contrbtr_disclsr>
        <p>Disclosure: Marinella Calle, PhD, CMPP, has disclosed no relevant financial relationships.</p>
      </contrbtr_disclsr>
    </contrbtr_element>
    <contrbtr_element>
      <contrbtr_nm>Maria B. Uravich, BSc</contrbtr_nm>
      <contrbtr_title>
        <p>Scientific Director, WebMD Global, LLC</p>
      </contrbtr_title>
      <contrbtr_bio/>
      <contrbtr_disclsr>
        <p>Disclosure: Maria B. Uravich, BSc, has disclosed no relevant financial relationships</p>
      </contrbtr_disclsr>
    </contrbtr_element>
  </contrbtr_group>
  <contrbtr_group>
    <contrbtr_type_lbl>Content Reviewer</contrbtr_type_lbl>
    <contrbtr_element>
      <contrbtr_nm>Nafeez Zawahir, MD</contrbtr_nm>
      <contrbtr_title>
        <p>CME Clinical Director</p>
      </contrbtr_title>
      <contrbtr_bio/>
      <contrbtr_disclsr>
        <p>Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.</p>
      </contrbtr_disclsr>
    </contrbtr_element>
  </contrbtr_group>
  <contrbtr_bulk_info/>
  <contrbtr_post_content/>
  <supprtr_grant_group>
    <supprtr_grant_attr>/webmd/professional_assets/medscape/images/grant_attribution/viiv-ieg.gif</supprtr_grant_attr>
  </supprtr_grant_group>
  <body_label>Body</body_label>
  <toc_element>
    <TOCLabel/>
    <toc_type>Default</toc_type>
    <sec_element>
      <sec_header/>
      <subsec_element>
        <subsec_header/>
        <slide_intro/>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/896/127/Slide1.png</sec_img>
          <sec_label>Slide 1.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>Faculty</h3>
          </sec_txt>
          <sec_alt_txt>Slide 1.</sec_alt_txt>
          <qna_form/>
        </slide_grp>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/896/127/Slide2.png</sec_img>
          <sec_label>Slide 2.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>Introduction</h3>
          </sec_txt>
          <sec_alt_txt>Slide 2.</sec_alt_txt>
          <qna_form/>
        </slide_grp>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/896/127/Slide3.png</sec_img>
          <sec_label>Slide 3.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>Disclaimer</h3>
          </sec_txt>
          <sec_alt_txt>Slide 3.</sec_alt_txt>
          <qna_form/>
        </slide_grp>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/896/127/Slide4.png</sec_img>
          <sec_label>Slide 4.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>HIV-1 Entry: The First Step in the HIV-1 Life Cycle<sup type="ref">[1,2]</sup>
</h3>
<ul>
    <li>The molecular machine that is at the core of HIV entry is called the HIV envelope (Env) trimer, which is placed at the surface of virus particles</li>
</ul>
          </sec_txt>
          <sec_alt_txt>Slide 4.</sec_alt_txt>
          <qna_form/>
        </slide_grp>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/896/127/Slide5.png</sec_img>
          <sec_label>Slide 5.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>Key Viral Protein for HIV Entry<sup type="ref">[3-5]</sup>
</h3>
<ul>
    <li>After the HIV virus attaches to CD4, the membrane of the virus and the host's cell surface membrane need to fuse</li>
    <li>After the fusion process, the genetic material from the virus enters the host cell</li>
</ul>
          </sec_txt>
          <sec_alt_txt>Slide 5.</sec_alt_txt>
          <qna_form>3</qna_form>
        </slide_grp>
      </subsec_element>
    </sec_element>
    <sec_element>
      <sec_header/>
      <subsec_element>
        <subsec_header/>
        <slide_intro/>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/896/127/Slide6.png</sec_img>
          <sec_label>Slide 6.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>HIV-1 Immune Pressure and Evasion<sup type="ref">[2]</sup>
</h3>
<ul>
    <li>Most viruses are not subject to huge immune pressure during the entry process</li>
    <li>During the chronic phase of HIV infection, very high levels of antibody are present</li>
    <li>These antibodies are trying to recognize the virus surface, where the only viral protein is the HIV Env trimer</li>
    <li>The HIV Env trimer has evolved many ways to evade the antibody attack, differentiating itself from other viruses</li>
</ul>
          </sec_txt>
          <sec_alt_txt>Slide 6.</sec_alt_txt>
          <qna_form/>
        </slide_grp>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/896/127/Slide7.png</sec_img>
          <sec_label>Slide 7.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>Overall Outline of Type 1 Fusion Mechanism of HIV-1 Entry Resolved 20 Years Ago<sup type="ref">[6]</sup>
</h3>
<ul>
    <li>Many viruses like influenza and Ebola use the same mechanism of entry, which is called a type 1 fusion mechanism</li>
    <li>At the very start of the HIV entry process, the glycoprotein (gp)160 protein is cleaved into the exterior gp120 protein and the transmembrane gp41 protein, which is the fusion machine</li>
    <li>These molecules bind to CD4 and the co-receptor, and this process triggers what is called a pre-hairpin intermediate, whereby part of the fusion machinery, called the fusion peptide, is thrown into the target cell membrane
    <ul>
        <li>Small molecule inhibitors currently under investigation can inhibit this step and the subsequent conformational changes</li>
    </ul>
    </li>
    <li>If inhibition does not take place, the pre-hairpin intermediate turns into a hairpin, which then fuses membranes in a process that is not yet entirely known</li>
    <li>Ultimately, the process ends with postfusion structures and the fusion of the viral membrane with the target cell membrane</li>
</ul>
          </sec_txt>
          <sec_alt_txt>Slide 7.</sec_alt_txt>
          <qna_form/>
        </slide_grp>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/896/127/Slide8.png</sec_img>
          <sec_label>Slide 8.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>HIV-1 Env Entry Pathway Contains Additional Prefusion States<sup type="ref">[5]</sup>
</h3>
<ul>
    <li>The Env trimer has several conformational states that it reaches in order to evade immune recognition</li>
</ul>
          </sec_txt>
          <sec_alt_txt>Slide 8.</sec_alt_txt>
          <qna_form/>
        </slide_grp>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/896/127/Slide9.png</sec_img>
          <sec_label>Slide 9.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>Understand Entry and Immune Evasion with Atomic-Level Insights<sup type="ref">[7-9]</sup>
</h3>
<ul>
    <li>The different structural states of the HIV entry process have been studied at the atomic level in an effort to design therapeutic products for HIV treatment</li>
</ul>
          </sec_txt>
          <sec_alt_txt>Slide 9.</sec_alt_txt>
          <qna_form/>
        </slide_grp>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/896/127/Slide10.png</sec_img>
          <sec_label>Slide 10.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>Understand Entry and Immune Evasion with Atomic-Level Insights (cont)<sup type="ref"> [7-9]</sup>
</h3>
          </sec_txt>
          <sec_alt_txt>Slide 10.</sec_alt_txt>
          <qna_form/>
        </slide_grp>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/896/127/Slide11.png</sec_img>
          <sec_label>Slide 11.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>Outline</h3>
          </sec_txt>
          <sec_alt_txt>Slide 11.</sec_alt_txt>
          <qna_form/>
        </slide_grp>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/896/127/Slide12.png</sec_img>
          <sec_label>Slide 12.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>Link Ligand-Induced States to smFRET Measurements<sup type="ref">[10]</sup>
</h3>
          </sec_txt>
          <sec_alt_txt>Slide 12.</sec_alt_txt>
          <qna_form/>
        </slide_grp>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/896/127/Slide13.png</sec_img>
          <sec_label>Slide 13.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>smFRET Tags In V1-V4 Sample Conformational Flexibility of HIV-1 Env Trimer on Infectious Virus<sup type="ref">[10]</sup>
</h3>
          </sec_txt>
          <sec_alt_txt>Slide 13.</sec_alt_txt>
          <qna_form/>
        </slide_grp>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/896/127/Slide14.png</sec_img>
          <sec_label>Slide 14.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>Functional Env Trimer Transitions Between 3 Prefusion Conformation States<sup type="ref">[10]</sup>
</h3>
<ul>
    <li>Viruses such as influenza or Ebola have a single prefusion conformation state</li>
    <li>With HIV, the Env trimer transitions between different states</li>
</ul>
          </sec_txt>
          <sec_alt_txt>Slide 14.</sec_alt_txt>
          <qna_form/>
        </slide_grp>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/896/127/Slide15.png</sec_img>
          <sec_label>Slide 15.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>State 1 Was Preferentially Recognized by Most Broadly Neutralizing Antibodies<sup type="ref">[10]</sup>
</h3>
<ul>
    <li>Adding certain antibodies will force the Env molecule into a particular state</li>
    <li>This effect occurs with many antibodies, and also with small molecules such as temsavir (formerly BMS-626529)</li>
    <li>Both laboratory-adapted virus and primary isolate show similar responses, meaning that this process is a "general" way that the HIV Env trimer uses to enter cells</li>
</ul>
          </sec_txt>
          <sec_alt_txt>Slide 15.</sec_alt_txt>
          <qna_form/>
        </slide_grp>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/896/127/Slide16.png</sec_img>
          <sec_label>Slide 16.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>Determination of Env Trimer Structure Used 2 Antibodies For Crystallization<sup type="ref">[11]</sup>
</h3>
          </sec_txt>
          <sec_alt_txt>Slide 16.</sec_alt_txt>
          <qna_form/>
        </slide_grp>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/896/127/Slide17.png</sec_img>
          <sec_label>Slide 17.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>Initial Interaction of CD4 With the HIV-1 Env Trimer<sup type="ref">[12]</sup>
</h3>
          </sec_txt>
          <sec_alt_txt>Slide 17.</sec_alt_txt>
          <qna_form/>
        </slide_grp>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/896/127/Slide18.png</sec_img>
          <sec_label>Slide 18.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>Measurement of smFRET Directly on Soluble Env Trimers<sup type="ref">[12-14]</sup>
</h3>
<ul>
    <li>The initial single-molecule fluorescence resonance energy transfer (smFRET) measurements were performed on the surface of the infectious virus
    <ul>
        <li>The crystal structures are actually solubilized protein</li>
    </ul>
    </li>
    <li>An alternative way to study these structures is to take the solubilized protein, the trimer, place the smFRET tags, attach these to a glass slide, and look at the smFRET measurements</li>
</ul>
          </sec_txt>
          <sec_alt_txt>Slide 18.</sec_alt_txt>
          <qna_form/>
        </slide_grp>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/896/127/Slide19.png</sec_img>
          <sec_label>Slide 19.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>Insights on Structure of Env Trimers<sup type="ref">[13,15,16]</sup>
</h3>
          </sec_txt>
          <sec_alt_txt>Slide 19.</sec_alt_txt>
          <qna_form/>
        </slide_grp>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/896/127/Slide20.png</sec_img>
          <sec_label>Slide 20.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>Structural Transformation: State 2 to State 3<sup type="ref">[7,16]</sup>
</h3>
          </sec_txt>
          <sec_alt_txt>Slide 20.</sec_alt_txt>
          <qna_form/>
        </slide_grp>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/896/127/Slide21.png</sec_img>
          <sec_label>Slide 21.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>Summary: HIV-1 Env Structure</h3>
          </sec_txt>
          <sec_alt_txt>Slide 21.</sec_alt_txt>
          <qna_form/>
        </slide_grp>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/896/127/Slide22.png</sec_img>
          <sec_label>Slide 22.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>Outline</h3>
          </sec_txt>
          <sec_alt_txt>Slide 22.</sec_alt_txt>
          <qna_form/>
        </slide_grp>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/896/127/Slide23.png</sec_img>
          <sec_label>Slide 23.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>Inhibitors That Bind to States 1 and 2 Neutralize Primary Isolates; Those That Only Bind State 3 Often Do Not<sup type="ref">[5,17]</sup>
</h3>
<ul>
    <li>The way HIV evades the immune system is by staying in state 1 and state 2, and only roughly transitioning to state 3 when it needs to enter the host cell</li>
    <li>Therefore, the best entry inhibitors are those that can bind to state 1 and state 2</li>
</ul>
          </sec_txt>
          <sec_alt_txt>Slide 23.</sec_alt_txt>
          <qna_form>4</qna_form>
        </slide_grp>
      </subsec_element>
    </sec_element>
    <sec_element>
      <sec_header/>
      <subsec_element>
        <subsec_header/>
        <slide_intro/>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/896/127/Slide24.png</sec_img>
          <sec_label>Slide 24.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>Entry Inhibitors and Targets<sup type="ref">[18-24]</sup>
</h3>
          </sec_txt>
          <sec_alt_txt>Slide 24.</sec_alt_txt>
          <qna_form/>
        </slide_grp>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/896/127/Slide25.png</sec_img>
          <sec_label>Slide 25.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>Fostemsavir (BMS-663068)<sup type="ref">[25,26]</sup>
</h3>
<ul>
    <li>The small molecule temsavir is a very potent attachment inhibitor; however, it has poor biological activity due to its hydrophobic nature</li>
    <li>Addition of a methyl phosphate to the structure results in the small molecule called fostemsavir (BMS-663068), which has very good bioavailability</li>
</ul>
          </sec_txt>
          <sec_alt_txt>Slide 25.</sec_alt_txt>
          <qna_form/>
        </slide_grp>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/896/127/Slide26.png</sec_img>
          <sec_label>Slide 26.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>Fostemsavir: BRIGHTE Phase 3 Study<sup type="ref">[24,27]</sup>
</h3>
          </sec_txt>
          <sec_alt_txt>Slide 26.</sec_alt_txt>
          <qna_form/>
        </slide_grp>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/896/127/Slide27.png</sec_img>
          <sec_label>Slide 27.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>Crystal Structures of HIV-1-Env Trimer With BMS-378806 and Its Derivative, Temsavir<sup type="ref">[11,28]</sup>
</h3>
          </sec_txt>
          <sec_alt_txt>Slide 27.</sec_alt_txt>
          <qna_form/>
        </slide_grp>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/896/127/Slide28.png</sec_img>
          <sec_label>Slide 28.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>Lattice-Chaperone Strategy: Mutations for Improvement<sup type="ref">[29]</sup>
</h3>
          </sec_txt>
          <sec_alt_txt>Slide 28.</sec_alt_txt>
          <qna_form/>
        </slide_grp>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/896/127/Slide29.png</sec_img>
          <sec_label>Slide 29.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>Summary: Chaperone Mutations for Improvement<sup type="ref">[29]</sup>
</h3>
<ul>
    <li>Approximately twice as much information (vs what was previously available) is obtained by using the lattice-chaperone strategy</li>
    <li>Structures can now be read at about 3 Å</li>
</ul>
          </sec_txt>
          <sec_alt_txt>Slide 29.</sec_alt_txt>
          <qna_form/>
        </slide_grp>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/896/127/Slide30.png</sec_img>
          <sec_label>Slide 30.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>New Lattice Appears to Be Improved<sup type="ref">[7,11,29,30]</sup>
</h3>
          </sec_txt>
          <sec_alt_txt>Slide 30.</sec_alt_txt>
          <qna_form/>
        </slide_grp>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/896/127/Slide31.png</sec_img>
          <sec_label>Slide 31.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>New Crystal Allows for the Determination of Structures With Trimers From Diverse HIV-1 Strains<sup type="ref">[29]</sup>
</h3>
<ul>
    <li>New lattice also allows researchers to look for HIV-1 variability</li>
    <li>The crystal lattice currently available is composed purely of antibodies binding to the Env trimer; with these in place, crystals can be formed using all sorts of different trimers captured within the crystal lattice</li>
    <li>This technique has allowed the observation of the small molecule BMS-386150 bound to different HIV strains</li>
</ul>
          </sec_txt>
          <sec_alt_txt>Slide 31.</sec_alt_txt>
          <qna_form>5</qna_form>
        </slide_grp>
      </subsec_element>
    </sec_element>
    <sec_element>
      <sec_header/>
      <subsec_element>
        <subsec_header/>
        <slide_intro/>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/896/127/Slide32.png</sec_img>
          <sec_label>Slide 32.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>Co-Crystal Structures Show Potential Additional Functional Group</h3>
          </sec_txt>
          <sec_alt_txt>Slide 32.</sec_alt_txt>
          <qna_form/>
        </slide_grp>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/896/127/Slide33.png</sec_img>
          <sec_label>Slide 33.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>Structural "Freezing" by Temsavir binding<sup type="ref">[16,28]</sup>
</h3>
          </sec_txt>
          <sec_alt_txt>Slide 33.</sec_alt_txt>
          <qna_form/>
        </slide_grp>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/896/127/Slide34.png</sec_img>
          <sec_label>Slide 34.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>Summary: Small Molecule Entry Inhibitors</h3>
          </sec_txt>
          <sec_alt_txt>Slide 34.</sec_alt_txt>
          <qna_form/>
        </slide_grp>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/896/127/Slide35.png</sec_img>
          <sec_label>Slide 35.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>Concluding Remarks</h3>
          </sec_txt>
          <sec_alt_txt>Slide 35.</sec_alt_txt>
          <qna_form/>
        </slide_grp>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/896/127/Slide36.png</sec_img>
          <sec_label>Slide 36.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>Thank You</h3>
          </sec_txt>
          <sec_alt_txt>Slide 36.</sec_alt_txt>
          <qna_form/>
        </slide_grp>
      </subsec_element>
      <subsec_element>
        <subsec_header/>
        <slide_intro>
          <p>
<em>This content has been condensed for improved clarity.</em>
</p>
        </slide_intro>
      </subsec_element>
    </sec_element>
    <pg_footnotes/>
    <toc_label/>
  </toc_element>
  <toc_element>
    <toc_label>
      <p>Abbreviations</p>
    </toc_label>
    <toc_type>Sidebar</toc_type>
    <pg_footnotes/>
    <sec_element>
      <sec_header>
        <p>Abbreviations</p>
      </sec_header>
      <subsec_element>
        <subsec_header/>
        <slide_intro>
          <p>3D = three-dimensional<br/>
AE = adverse event<br/>
ART = antiretroviral therapy<br/>
BID = twice daily<br/>
CCR5 = C-C chemokine receptor type 5<br/>
CXCR = CXC chemokine receptor<br/>
CXCR4 = CXC chemokine receptor type 4<br/>
Env = envelope<br/>
Fab = antigen-binding fragment<br/>
gp = glycoprotein<br/>
GPCR = G-protein-coupled receptor<br/>
HTE = heavily treatment-experienced <br/>
Ig = immunoglobulin<br/>
rxn = resolution<br/>
smFRET = single-molecule fluorescence resonance energy transfer</p>
        </slide_intro>
      </subsec_element>
    </sec_element>
  </toc_element>
  <toc_element>
    <toc_label/>
    <toc_type>References</toc_type>
    <pg_footnotes/>
    <sec_element>
      <sec_header/>
      <subsec_element>
        <subsec_header/>
        <slide_intro>
          <ol>
    <li>Kuritzkes DR. HIV-1 entry inhibitors: an overview. <em>Curr Opin HIV AIDS</em>. 2009;4:82-87.</li>
    <li>Barré-Sinoussi F, Ross AL, Delfraissy JF. <em>Nat Rev Microbiol.</em> 2013;11:877-883.</li>
    <li>Klasse J. The molecular basis of HIV entry. <em>Cell Microbiol.</em> 2012;14:1183-1192</li>
    <li>Malik T, Chauhan G, Rath G, et al. "Fusion and binding inhibition" key target for HIV-1 treatment and pre-exposure prophylaxis: targets, drug delivery and nanotechnology approaches. <em>Drug Delivery</em>. 2017;24:608-621.</li>
    <li>Acharya P, Lusvarghi S, Bewley CA, et al. HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth. <em>Exp Opin Ther Targets.</em> 2015;19:765-783.</li>
    <li>Chan DC, Kim PS. HIV entry and its inhibition. <em>Cell. </em>1998;93:681-684.</li>
    <li>Stewart-Jones GB, Soto C, Lemmin T, et al. Trimeric HIV-1-Env structures define glycan shields from clades A, B, and G. <em>Cell</em>. 2016;165:813-826.</li>
    <li>Kwong P, Wyatt R, Robinson J, et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. <em>Nature</em>. 1998;393:648-659.</li>
    <li>Wu B, Chien EY, Mol CD, et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. <em>Science</em>. 2010;330:1066-1071</li>
    <li>Munro JB, Gorman J, Ma X, et al. Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions. <em>Science</em>. 2014;346:759-763.</li>
    <li>Pancera M, Zhou T, Druz A, et al. Structure and immune recognition of trimeric pre-fusion HIV-1 Env. <em>Nature</em>. 2014;514:455-461.</li>
    <li>Liu Q, Acharya P, Dolan MA, et al. Quaternary contact in the initial interaction of CD4 with the HIV-1 envelope trimer. <em>Nat Struct Mol Biol</em>. 2017;24:370-378.</li>
    <li>Lu M, Ma X, Castillo-Menendez LR, et al. Single-molecule FRET reveals an additional conformational state of HIV-1 envelope glycoprotein critical for vaccine design. <em>Biophysical J</em>. 2018;114(suppl 1):27a.</li>
    <li>Kwon YD, Pancera M, Acharya P, et al. Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env. <em>Nat Struct Mol Biol.</em> 2015;22:522-531.</li>
    <li>Liu J, Bartesaghi A, Borgnia MJ, et al. Molecular architecture of native HIV-1 gp120 trimers. <em>Nature</em>. 2008;455:109-113.</li>
    <li>Ozorowski G, Pallesen J, de Val N, et al. Open and closed structures reveal allostery and pliability in the HIV-1 envelope spike. <em>Nature</em>. 2017;547:360-363.</li>
    <li>Kwon YD, LaLonde JM, Yang Y,  et al. Crystal structures of HIV-1 gp120 envelope glycoprotein in complex with NBD analogues that target the CD4-binding site. <em>PLoS One.</em> 2014;9:e85940</li>
    <li>Celsentri® [package insert]. Pfizer, Inc: 2007.</li>
    <li>Maraviroc (HIV treatment). AIDSinfo website. https://aidsinfo.nih.gov/drugs/408/maraviroc--hiv-treatment/37/professional<a href="">. </a>Accessed April 16, 2018.</li>
    <li>Fuzeon® [package insert]. Hoffman-LaRoche, Inc; 2003.</li>
    <li>Hardy H, Skolnik PR. Enfuvirtide, a new fusion inhibitor for therapy of human immunodeficiency virus infection. <em>Pharmacotherapy</em>. 2004;24:198-211.</li>
    <li>Iacob SA, Iacob DG. Ibalizumab targeting CD4 receptors, an emerging molecule in HIV therapy. <em>Front Microbiol. </em>2017;8:2323.</li>
    <li>Reichert JM. Antibodies to watch in 2017. <em>MAbs. </em>2017;9:167-181.</li>
    <li>Kozal M, et al. Phase 3 study of fostemsavir in heavily treatment-experienced HIV-1 infected participants: day 8 and week 24 primary efficacy and safety results (BRIGHTE study, formerly 205888/AI438-047). Presented at: 16th European AIDS Conference; October 25-27, 2017; Milan, Italy. Abstract PS8/5.</li>
    <li>Lalezari JP, Latiff GH, Brinson C, et al. Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial. <em>Lancet HIV.</em> 2015;2:e427-e437.</li>
    <li>Thompson M, Lalezari JP, Kaplan R, et al. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized controlled trial. <em>Antivir Ther.</em> 2017;22:215-223.</li>
    <li>Fostemsavir controls viral load in half of people with highly drug-resistant HIV. AIDSmap website. http://www.aidsmap.com/page/3185707/. Accessed April 16, 2018.</li>
    <li>Pancera M, Lai YT, Bylund T, et al. Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529. <em>Nat Chem Biol. 2017</em>; 13: 1115-1122.</li>
    <li>Kwong PD. HIV Env: Structure, function, and inhibition thereof. Presented at: Conference on Retroviruses and Opportunistic Infections (CROI); March 4-7, 2018; Boston, MA, USA. Abstract 98.</li>
    <li>Garces F, Lee JH, de Val N, et al. Affinity maturation of a potent family of HIV antibodies is primarily focused on accommodating or avoiding glycans. <em>Immunity</em>. 2015; 43:1053-1063.</li>
</ol>
        </slide_intro>
      </subsec_element>
    </sec_element>
  </toc_element>
  <back_label>Back Matter</back_label>
  <ref_grp>
    <ref_item/>
  </ref_grp>
  <cpyrt_holder>
    <p>WebMD Global, LLC</p>
  </cpyrt_holder>
  <cpyrt_ovrd/>
  <disclmr_ovrd/>
  <bkmtr_front>
    <p>
<strong>Disclaimer</strong>
</p>
<p>The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.</p>
<p>The material presented here does not necessarily reflect the views of WebMD Global, LLC or companies that support educational programming on medscape.org. These materials may discuss therapeutic products that have not been approved by the European Medicines Agency for use in Europe and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.</p>
  </bkmtr_front>
  <bkmtr_glossary/>
  <bkmtr_ack/>
  <bkmtr_discl/>
  <bkmtr_funding/>
  <bkmtr_reprnt_addr/>
  <bkmtr_abbr_notes/>
  <bkmtr_last/>
  <img_ttl_bkgrd/>
  <img_publ_logo/>
</prof_article_slide_presentation>
